Stockscreener 앱 받기
39.13
0.08%
0.03
시장 영업 전:
39.80
0.67
+1.71%
전일 마감가:
$39.10
열려 있는:
$39.38
하루 거래량:
2.81M
Relative Volume:
1.29
시가총액:
$8.07B
수익:
$2.10B
순이익/손실:
$402.17M
주가수익비율:
20.21
EPS:
1.9357
순현금흐름:
$403.87M
1주 성능:
+1.03%
1개월 성능:
+8.15%
6개월 성능:
-12.99%
1년 성능:
-18.83%
1일 변동 폭
$38.84
$39.56
1주일 범위
$38.59
$39.90
52주 변동 폭
$32.53
$57.81
Qiagen Nv Stock (QGEN) Company Profile
Compare QGEN vs TMO, DHR, IDXX, NTRA, A
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
QGEN
Qiagen Nv
|
39.13 | 8.06B | 2.10B | 402.17M | 403.87M | 1.9357 |
TMO
Thermo Fisher Scientific Inc
|
513.33 | 186.32B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
193.72 | 134.82B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
537.58 | 41.53B | 4.45B | 1.10B | 1.06B | 13.59 |
NTRA
Natera Inc
|
276.27 | 38.88B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
133.39 | 37.52B | 7.23B | 1.41B | 1.09B | 4.979 |
Qiagen Nv Stock (QGEN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-14 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2026-03-13 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2026-01-22 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2025-12-11 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2025-06-24 | 개시 | Barclays | Overweight |
| 2025-04-04 | 다운그레이드 | Redburn Atlantic | Buy → Neutral |
| 2025-02-19 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2025-01-06 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-12-10 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-10-17 | 다운그레이드 | HSBC Securities | Buy → Hold |
| 2024-06-27 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2023-12-19 | 개시 | Wells Fargo | Equal Weight |
| 2023-12-13 | 개시 | Wolfe Research | Peer Perform |
| 2023-12-07 | 업그레이드 | Goldman | Neutral → Buy |
| 2023-09-12 | 개시 | Robert W. Baird | Outperform |
| 2023-05-23 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-10-18 | 개시 | Morgan Stanley | Equal-Weight |
| 2022-01-18 | 업그레이드 | DZ Bank | Hold → Buy |
| 2021-10-15 | 재개 | Cowen | Market Perform |
| 2021-10-14 | 개시 | Redburn | Buy |
| 2021-07-14 | 다운그레이드 | Kepler | Buy → Hold |
| 2021-06-03 | 개시 | Goldman | Neutral |
| 2020-10-06 | 재개 | BofA Securities | Buy |
| 2020-09-28 | 업그레이드 | Kepler | Hold → Buy |
| 2020-08-24 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-08-20 | 재개 | JP Morgan | Overweight |
| 2020-08-17 | 업그레이드 | Berenberg | Hold → Buy |
| 2020-08-14 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2020-08-14 | 업그레이드 | Exane BNP Paribas | Neutral → Outperform |
| 2020-03-04 | 다운그레이드 | Berenberg | Buy → Hold |
| 2020-01-08 | 개시 | Wells Fargo | Equal Weight |
| 2020-01-07 | 개시 | Citigroup | Neutral |
| 2019-12-26 | 재개 | BofA/Merrill | Underperform |
| 2019-11-15 | 개시 | Stifel | Hold |
| 2019-11-14 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2019-11-14 | 업그레이드 | JP Morgan | Underweight → Overweight |
| 2019-11-14 | 업그레이드 | Kepler | Reduce → Hold |
| 2019-10-17 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2019-10-09 | 다운그레이드 | Kepler | Hold → Reduce |
| 2019-10-08 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2019-10-08 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2019-10-08 | 다운그레이드 | JP Morgan | Neutral → Underweight |
모두보기
Qiagen Nv 주식(QGEN)의 최신 뉴스
Qiagen N.V. highlights digital PCR expansion. Stock trades near recent highs on Nasdaq - AD HOC NEWS
Qiagen earnings calendar and diagnostics pipeline, shares watched by international investors - AD HOC NEWS
Qiagen earnings calendar stands out this week, shares steady on Xetra - AD HOC NEWS
Qiagen steady ahead of earnings, shares watched by analysts - AD HOC NEWS
QIAGEN NV Actuals & Estimates (TURQUOISE:QIAD) - TradingView
The QIAamp DNA Mini Kit from Qiagen N.V.quiet lab workhorse for clean samples - AD HOC NEWS
Qiagen N.V.(NYSE: QGEN) added to Russell 1000 Dynamic Index - marketscreener.com
Qiagen consistent with diagnostics strategy, shares follow sector trend - AD HOC NEWS
QIAGEN NV Actuals & Estimates (AQUISUK:QIAD) - TradingView
Qiagen expands QIAcuity gene expression tools, shares remain muted on NYSE - AD HOC NEWS
QIAGEN NV Actuals & Estimates (VIE:QGE4) - TradingView
Qiagen N.V. refines diagnostics portfolio, shares backed by long-term strategy - AD HOC NEWS
Qiagen steadies after recent pullback, shares tracked on NYSE and Xetra - Ad-hoc-news.de
Enterprise value to EBIT forward of Qiagen N.V. – NYSE:QGEN - TradingView
Qiagen updates its diagnostics focus, shares anchored in health-care demand - AD HOC NEWS
QGEN Forecast — Price Target — Prediction for 2027 - TradingView
Price to sales forward of Qiagen N.V. – NYSE:QGEN - TradingView
Qiagen earnings calendar and diagnostics outlook, shares in focus for Nasdaq investors - AD HOC NEWS
Qiagen extends its recent high, shares near 52-week peak on NYSE and Xetra - AD HOC NEWS
Bloodstream Infection Testing Market Size to Reach USD 1,404.68 Million by 2035 | SNS Insider - GlobeNewswire Inc.
QIAGEN NV Actuals & Estimates (BIVA:QIA/N) - TradingView
Qiagen N.V. updates earnings calendar, shares tracked against diagnostics peers - AD HOC NEWS
PTA-DD: QIAGEN N.V.: Managers' transactions announcement according to article 19 MAR - TradingView
Managers' transactions announcement according to article 19 MAR - TradingView
Qiagen adjusts portfolio in Europe, shares track diagnostics peers - Ad-hoc-news.de
QIAGEN NV Actuals & Estimates (NYSE:QGEN) - TradingView
Qiagen publishes new sustainability report, shares backed by fresh analyst support - Ad-hoc-news.de
Enterprise value to EBITDA forward of Qiagen N.V. – NYSE:QGEN - TradingView
Kepler Cheuvreux Initiates Qiagen Coverage at Hold - marketscreener.com
Is Qiagen's (QGEN) Digital PCR Expansion Quietly Redefining Its Competitive Moat in Biopharma Tools? - simplywall.st
Qiagen N : Sustainability Report (ca ab 1305 voluntary carbon market disclosure 2026) - marketscreener.com
Qiagen N : Sustainability Report (ca ab 1305 voluntary carbon market disclosure) - marketscreener.com
Qiagen NV Annual Shareholders Meeting Transcript - GuruFocus
Qiagen (QGEN) Short Interest & Short Float | Updated Jun 2026 - MarketBeat
Morgan Stanley Upgrades Qiagen to Overweight, Raises PT - marketscreener.com
QGEN Upgraded by Morgan Stanley -- Price Target Raised to $42.00 - GuruFocus
Barclays Maintains Qiagen NV(QGEN.US) With Hold Rating, Maintains Target Price $38 - Moomoo
Qiagen annual meeting in Venlo, shares under DAX investor scrutiny - Ad-hoc-news.de
PTA-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG - TradingView
Release according to Article 40, Section 1 of the WpHG - TradingView
Qiagen updates draw analyst attention, shares react on NYSE and Xetra - Ad-hoc-news.de
Qiagen Raised to Overweight From Equal-Weight by Morgan Stanley - Moomoo
Qiagen gets a DZ Bank lift, analyst consensus shapes the shares - Ad-hoc-news.de
QIAGEN NV : Gets a Buy rating from DZ Bank - marketscreener.com
Qiagen NV (QGEN) Institutional Confidence - TradingKey
Morgan Stanley Upgrades Qiagen NV(QGEN.US) to Buy Rating, Raises Target Price to $42 - Moomoo
Qiagen strategy and digital PCR expansion, shares tracked on Xetra and NYSE - AD HOC NEWS
Qiagen NV: QIAGEN N.V.Share Consolidation/Cash Distribution Option Symbol: QGEN New Symbol: QGEN1 - Moomoo
Qiagen Stockweekly outlook with earnings ahead - AD HOC NEWS
Qiagen NV (QGEN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Goldman Sachs Reports 2.87% Stake in Qiagen via Equity and Derivatives - The Globe and Mail
Qiagen Nv (QGEN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.92%
자본화:
|
볼륨(24시간):